Pall to Acquire Chromatography Business from Ciphergen Biosystems.EAST HILLS, N.Y. -- Pall Corporation Pall Corporation NYSE: PLL, formerly Micro Metallic Company, is an East Hills, New York based global business in the diverse field of filtration, separations and purification. Total revenues for fiscal 2006 were $2 billion, with over 11,000 employees and $56. (NYSE NYSE See: New York Stock Exchange : PLL PLL - phase-locked loop ) today announced it will acquire the BioSepra Process Division from Ciphergen Biosystems, Inc. (Nasdaq: CIPH CIPH Canadian Institute of Plumbing and Heating ) for a purchase price of approximately $32 million, net of cash and debt. The transaction is expected to close within 45 days. The BioSepra Process Division develops, manufactures and markets chromatography sorbents that greatly simplify protein purification development and significantly improve biopharmaceutical manufacturing productivity. Eric Krasnoff, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Pall Corporation, said," Biosepra is a welcome addition to Pall's Life Sciences business. Their innovative and broad range of chromatography chemistries fit in well with our significant market position in drug discovery and protein purification. We are very pleased to strengthen Pall's ability to serve the needs of our Biotechnology customers." Pall and Ciphergen also announced an alliance to develop and promote Ciphergen's patented SELDI SELDI Surface Enhanced Laser Desorption/Ionization ProteinChip(R) technology as a bridge between the research lab and large scale drug production. This technology will be used to optimize chromatography resin selection for protein purification. William E. Rich, President and CEO of Ciphergen. "We are excited about working with Pall and their customers to continue expansion of our pioneering work in Process Proteomics in order to speed process development using our ProteinChip Systems for protein purification and expression optimization and process monitoring." Pall plans to establish Process Proteomics Service Centers that will assist customers in selecting and optimizing sorbents and membranes for the purification of proteins used in the production of therapeutic proteins and other bioprocess bi·o·proc·ess n. 1. A technique that produces a biological material, such as a genetically engineered microbial strain, for commercial use. 2. applications. The addition of these sorbent sorbent /sor·bent/ (sor´bent) an agent that sorbs; see absorbent and adsorbent. sorbent an agent that sorbs. technologies will enable Pall to provide a highly integrated solution for the bioprocess separations market. About Pall Corporation Pall Corporation is the leader in the rapidly growing fields of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicine transfusion medicine Blood banking A subspecialty of clinical pathology or internal medicine which is involved in Pt management through administration of blood cells and blood products including fresh-frozen plasma and cryoprecipitate; TM specialists are versant in , semiconductors, municipal drinking water drinking water supply of water available to animals for drinking supplied via nipples, in troughs, dams, ponds and larger natural water sources; an insufficient supply leads to dehydration; it can be the source of infection, e.g. leptospirosis, salmonellosis, or of poisoning, e.g. , aerospace and broad industrial markets. Total revenues are $1.77 billion. The company headquarters are in East Hills, New York East Hills is a village in Nassau County, New York on the North Shore of Long Island. It is considered part of the Greater Roslyn area, which is anchored by the Village of Roslyn. As of the United States 2000 Census, the village population was 6,842. with operations in about 40 countries. Visit Pall at www.pall.com. About Ciphergen Ciphergen's Biosystems Division develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research, and process proteomics applications, as well as a broad range of bioseparations media for protein purification and large scale production. ProteinChip Systems enable protein discovery, characterization, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Ciphergen's Diagnostics Division is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Additional information about Ciphergen can be found at www.ciphergen.com. This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company's success in enforcing its patents and protecting its proprietary products and manufacturing techniques; global and regional economic conditions and legislative, regulatory and political developments and its ability to achieve the savings anticipated from its cost reduction initiatives; and domestic and international competition in the Company's global markets. Additional information regarding these and other factors is available on the web at www.pall.com and is included in the Company's reports filed with the U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at: www.sec.gov. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion